ORLANDO — In this video from the American Academy of Ophthalmology meeting, Philip J. Ferrone, MD, discusses the TEASE-2 trial results in treating Stargardt disease with gildeuretinol.
The phase 2 trial included a heterogeneous population of Stargardt patients with an average age of 21 years at baseline with moderate disease severity and varying degrees of ellipsoid zone (EZ) loss. Over 2 years, 40 patients were treated with gildeuretinol (Alkeus), and 39 patients received placebo.
While the primary endpoint of degree of EZ loss or photoreceptor loss was not statistically significant,